Analyst Clara Dong of Jefferies maintained a Buy rating on ImmunityBio, with a price target of $9.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clara Dong’s rating is based on ImmunityBio’s strategic advancements and regulatory progress. The company has received a conditional marketing authorization recommendation from the EMA for Anktiva in combination with BCG for treating BCG-unresponsive NMIBC-CIS. This recommendation is supported by promising trial results, where a significant percentage of patients achieved a complete response, demonstrating the therapy’s potential efficacy and durability.
Furthermore, ImmunityBio is actively engaging in regulatory discussions for additional indications, such as papillary disease, and is awaiting a decision on NCCN guideline inclusion, which could enhance prescription and reimbursement processes. The company’s ongoing trials, including those targeting BCG-naive NMIBC and NSCLC, indicate a robust pipeline and potential for further growth. These factors collectively contribute to Clara Dong’s Buy rating for ImmunityBio’s stock.
Dong covers the Healthcare sector, focusing on stocks such as BeOne Medicines, Cogent Biosciences, and Kymera Therapeutics. According to TipRanks, Dong has an average return of 11.1% and a 58.33% success rate on recommended stocks.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.